Halicin

Halicin
Clinical data
Trade names	Halicin
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 5-[(5-Nitro-1,3-thiazol-2-yl)sulfanyl]-1,3,4-thiadiazol-2-amine;
CAS Number	40045-50-9 ;
PubChem CID	11837140;
ChemSpider	10011699;
UNII	Y4KQC5P9B2;
ChEBI	CHEBI:146227;
ChEMBL	ChEMBL510038;
CompTox Dashboard (EPA)	DTXSID70474254 ;
Chemical and physical data
Formula	C5H3N5O2S3
Molar mass	261.29 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1=C(SC(=N1)SC2=NN=C(S2)N)[N+](=O)[O-];
	InChI InChI=1S/C5H3N5O2S3/c6-3-8-9-5(14-3)15-4-7-1-2(13-4)10(11)12/h1H,(H2,6,8); Key:NQQBNZBOOHHVQP-UHFFFAOYSA-N;

Halicin (SU-3327) is an experimental drug that acts as an enzyme inhibitor of c-Jun N-terminal kinase (JNK). Originally, it was researched for the treatment of diabetes, but development was discontinued for this application due to poor results in testing. In 2019, this molecule was found by an artificial intelligence (AI) model to show antibiotic properties against a number of bacteria.